|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The wonders of BMP9:From mesenchymal stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism to regenerative medicine显示文摘Although bone morphogenetic proteins(BMPs)initially showed effective induction of ectopic bone growth in muscle,it has since been determined that these proteins,as members of the TGF-b superfamily,play a diverse and critical array of biological roles.These roles include regulating skeletal and bone formation,angiogenesis,and development and homeostasis of multiple organ systems.Disruptions of the members of the TGF-b/BMP superfamily result in severe skeletal and extra-skeletal irregularities,suggesting high therapeutic potential from understanding this family of BMP proteins.Although it was once one of the least characterized BMPs,BMP9 has revealed itself to have the highest osteogenic potential across numerous experiments both in vitro and in vivo,with recent studies suggesting that the exceptional potency of BMP9 may result from unique signaling pathways that differentiate it from other BMPs.The effectiveness of BMP9 in inducing bone formation was recently revealed in promising experiments that demonstrated efficacy in the repair of critical sized cranial defects as well as compatibility with bone-inducing bio-implants,revealing the great translational promise of BMP9.Furthermore,emerging evidence indicates that,besides its osteogenic activity,BMP9 exerts a broad range of biological functions,including stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism.This review aims to summarize our current understanding of BMP9 across biology and the body. | Sami Mostafa Mikhail Pakvasa Elam Coalson Allen Zhu Alex Alverdy Hector Castillo Jiaming Fan Alex Li Yixiao Feng Di Wu Elliott Bishop Scott Du Mia Spezia Alissa Li Ofir Hagag Alison Deng Winny Liu Mingyang Li Sherwin S·Ho Aravind Athiviraham Michael J·Lee Jennifer Moriatis Wolf Guillermo A·Ameer Hue H·Luu Rex C·Haydon Jason Strelzow Kelly Hynes Tong-Chuan He Russell R·Reid | 2019 | Genes & Diseases2019，6，3： | 15 |
| 2 | Encapsulating peritoneal sclerosis显示文摘Encapsulating peritoneal sclerosis(EPS) is a debilitating condition characterized by a fibrocollagenous membrane encasing the small intestine, resulting in recurrent small bowel obstructions. EPS is most commonly associated with long-term peritoneal dialysis, though medications, peritoneal infection, and systemic inflammatory disorders have been implicated. Many cases remain idiopathic. Diagnosis is often delayed given the rarity of the disorder combined with non-specific symptoms and laboratory findings. Although cross-sectional imaging with computed tomography of the abdomen can be suggestive of the disorder, many patients undergo exploratory laparotomy for diagnosis. Mortality approaches 50% one year after diagnosis. Treatment for EPS involves treating the underlying condition or eliminating possible inciting agents(i.e. peritoneal dialysis, medications, infections) and nutritional support, frequently with total parenteral nutrition. EPSspecific treatment depends on the disease stage. In the inflammatory stage, corticosteroids are the treatment of choice, while in the fibrotic stage, tamoxifen may be beneficial. In practice, distinguishing between stages may be difficult and both may be used. Surgical intervention, consisting of peritonectomy and enterolysis, is timeconsuming and high-risk and is reserved for situations in which conservative medical therapy fails in institutions with surgical expertise in this area. Herein we review the available literature of the etiology, pathogenesis, diagnosis, and treatment of this rare, but potentially devastating disease. | Christopher J Danford Steven C Lin Martin P Smith Jacqueline L Wolf | 2018 | World Journal of Gastroenterology2018，24，28： | 13 |
| 3 | Transcriptomic landscape regulated by the 14 types of bone morphogenetic proteins(BMPs)in lineage commitment and differentiation of mesenchymal stem cells(MSCs)显示文摘Mesenchymal stem cells(MSCs)are ubiquitously-existing multipotent progenitors that can self-renew and differentiate into multiple lineages including osteocytes,chondrocytes,adipocytes,tenocytes and myocytes.MSCs represent one of the most commonly-used adult progenitors and serve as excellent progenitor cell models for investigating lineagespecific differentiation regulated by various cellular signaling pathways,such as bone morphogenetic proteins(BMPs).As members of TGFb superfamily,BMPs play diverse and important roles in development and adult tissues.At least 14 BMPs have been identified in mammals.Different BMPs exert distinct but overlapping biological functions.Through a comprehensive analysis of 14 BMPs in MSCs,we demonstrated that BMP9 is one of the most potent BMPs in inducing osteogenic differentiation of MSCs.Nonetheless,a global mechanistic view of BMP signaling in regulating the proliferation and differentiation of MSCs remains to be fully elucidated.Here,we conducted a comprehensive transcriptomic profiling in the MSCs stimulated by 14 types of BMPs.Hierarchical clustering analysis classifies 14 BMPs into three subclusters:an osteo/chondrogenic/adipogenic cluster,a tenogenic cluster,and BMP3 cluster.We also demonstrate that six BMPs(e.g.,BMP2,BMP3,BMP4,BMP7,BMP8,and BMP9)can induce ISmads effectively,while BMP2,BMP3,BMP4,BMP7,and BMP11 up-regulate Smad-independent MAP kinase pathway.Furthermore,we show that many BMPs can upregulate the expression of the signal mediators of Wnt,Notch and PI3K/AKT/mTOR pathways.While the reported transcriptomic changes need to be further validated,our expression profiling represents the first-of-its-kind to interrogate a comprehensive transcriptomic landscape regulated by the 14 types of BMPs in MSCs. | Linghuan Zhang Qing Luo Yi Shu Zongyue Zeng Bo Huang Yixiao Feng Bo Zhang Xi Wang Yan Lei Zhenyu Ye Ling Zhao Daigui Cao Lijuan Yang Xian Chen Bin Liu William Wagstaff Russell R*Reid Hue H*Luu Rex C*Haydon Michael J*Lee Jennifer Moriatis Wolf Zhou Fu Tong-Chuan He Quan Kang | 2019 | Genes & Diseases2019，6，3： | 11 |
| 4 | SEMS vs cSEMS in duodenal and small bowel obstruction:High risk of migration in the covered stent group显示文摘AIM:To compare clinical success and complications of uncovered self-expanding metal stents(SEMS)vs covered SEMS(cSEMS)in obstruction of the small bowel.METHODS:Technical success,complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed.The primary end points were rates of stent migration and overgrowth.Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival.The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.RESULTS:Thirty-two SEMS were implanted in 20 patients.In all patients,endoscopic stent implantation was successful.Stent migration was observed in 9 of16 cSEMS(56%)in comparison to 0/16 SEMS(0%)implantations(P=0.002).Stent overgrowth did not significantly differ between the two stent types(SEMS:3/16,19%;cSEMS:2/16,13%).One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy.Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ(HR=1.530,95%CI0.731-6.306;P=0.556).The mean follow-up was 57±71 d(range:1-275 d).CONCLUSION:SEMS and cSEMS placement is safe in small bowel tumor obstruction.However,cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS. | Oliver Waidmann Jrg Trojan Mireen Friedrich-Rust Christoph Sarrazin Wolf Otto Bechstein Frank Ulrich Stefan Zeuzem Jrg Gerhard Albert | 2013 | World Journal of Gastroenterology2013，19，37： | 4 |
| 5 | Liver Transplantation for Neuroendocrine Tumors in Europe—Results and Trends in Patient Selection: A 213-Case European Liver Transplant Registry Study显示文摘 | Yves Patrice Le Treut Emilie Grégoire Jürgen Klempnauer Jacques Belghiti Elisabeth Jouve Jan Lerut Denis Castaing Olivier Soubrane Olivier Boillot Georges Mantion Kia Homayounfar Manuel Bustamante Daniel Azoulay Philippe Wolf Marek Krawczyk Andreas Pasche | 2013 | Annals of Surgery2013，，5： | 3 |
| 6 | MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure显示文摘 | Thomas Thum Paolo Galuppo Christian Wolf Jan Fiedler Susanne Kneitz Linda W. van Laake Pieter A. Doevendans Christine L. Mummery Jürgen Borlak Axel Haverich Carina Gross Stefan Engelhardt Georg Ertl Johann Bauersachs | 2007 | Circulation2007，，3： | 3 |
| 7 | Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial显示文摘 | Gunnar Folprecht Thomas Gruenberger Wolf O Bechstein Hans-Rudolf Raab Florian Lordick J?rg T Hartmann Hauke Lang Andrea Frilling Jan Stoehlmacher Jürgen Weitz Ralf Konopke Christian Stroszczynski Torsten Liersch Detlev Ockert Thomas Herrmann Eray Goekkurt | 2010 | Lancet Oncology2010，，1： | 3 |
| 8 | 一种房颤风险评分系统的建立(Framingham心脏研究):基于社区的队列研究显示文摘背景房颤导致了发病率和病死率的显著上升。本研究旨在建立一种预测个体罹患房颤绝对风险的风险评分系统,并提供研究人员评价新危险因素的流程。方法作者评估了Framingham心脏研究中于1968年6月至1987年9月间进行了8044次检测的4764例参与者(55%为女性,年龄45~95岁)。此后,参与者被随访至房颤首发,随访期最长达10年。多变量Coxi回归确认出1(1年内罹患房颤的临床危险因素。次级分析纳入了常规超声心动图检测指标(5152例4参与者,7156次检测)对房颤风险进行再分层评估,并评价超声检测指标能否提高风险预测能力。结果4764例参与者中的457例4(10%)罹患房颤。年龄、性别、体重指数、收缩压、降压治疗、PR间期、有临床意义的心脏杂音及心力衰竭与房颤相关,并被纳入了风险评分模型(除体重指数P=0.08外,其余均为P〈0.05),模型的C统计量为0.78(95%CI0.76~0.80)。10年房颤风险随年龄变化:年龄〈65岁的人群中53例(1%)风险高于15%,而〉65岁的人群中为783例(27%)。为提高预测能力而纳入超声检测指标仅使模型C统计量略微增高,由0.78(95%C10.75~0.80)增至0.79(95%CI0.77~0.82:P=0.005)。超声心动图检测指标并不能改善风险再分层评估(P=0.18)。结论基于社区医疗中易得的临床因素建立的风险评分系统,有助于确认社区个体罹患房颤的风险,评估技术或标志物能否改善风险预测,以及针对高危个体采取预防措施。 | Renate B Schnabel Lisa M Sullivan Daniel Levy Michael J Pencina Joseph M Massaro Ralph B D'Agostino Sr Christopher Newton-Cheh Jennifer F Yamamoto Jared W Magnani Thomas M Tadros William B Kannel Thomas J Wang Patrick T Ellinor Philip A Wolf Ramachanclran S Vasan Emelia J Benjamin 黄刚(译) | 2009 | 世界临床医学2009，，9： | 2 |
| 9 | 美国重症肌无力基金会关于重症肌无力临床试验的建议显示文摘由美国重症肌无力基金会(MGFA)的医学科学建议委员会(MSAB)组成工作组,于2010年在美国和2011年在意大利召开专家共识会议讨论重症肌无力(MG)临床试验的问题,与会代表包括来自美国和欧洲的神经科医生、统计学家、企业界代表、MG患者以及MGFA和欧洲重症肌无力协会的平民代表。 | Benatar M Sanders DB Burns TM Cutter GR Guptill JT Baggi F Kaminski HJ Mantegazza R Meriggioli MN Quan J Wolfe GI 李海峰(摘译) 高翔(摘译) | 2013 | 中国神经免疫学和神经病学杂志2013，20，1： | 2 |
| 10 | Determining Lyapunov exponents from a time series 显示文摘 | Wolf A J Swift B Swinney H L | 1985 | Physica D1985，16，3： | 2 |
| 11 | Approximate dynamic models of embedded foundations in time domain 显示文摘 | Wolf J P Somini Dario R | 1986 | Earthquake Engineering and Structural Dynamics1986，14，： | 2 |
| 12 | Determining Lyapunov Exponents from a Time Series显示文摘 | Wolf A Swift J B Swinney H L | 1985 | Physica1985，16，： | 2 |
| 13 | A parallel sort merge JOIN algorithm for managing data skew显示文摘 | Wolf J L Dias D M Yu P S | 1993 | IEEE Transactions Parallel and Distributed Systems1993，4，1： | 2 |
| 14 | Quantitative structure-activity relationships and mixture-toxicity studies of alcohols and chlorohydrocarbons: reproducibility of effects on growth and reproduction of Daphnia magna 显示文摘 | Wolf De W Canton J H Deneer J W | 1988 | Aquatic Toxicology1988，12，1： | 1 |
| 15 | Structural acoustics finite element analysis of the aoutomobile passenger compartment: A review of current practice显示文摘 | Nefske N J Wolf J A Jr Howell L J | 1982 | Journal of Sound Vibration1982，80，2： | 1 |
| 16 | Objective methods for registration landmarks and determining cloud motions from satellite data显示文摘 | Endlich R M Wolf D E and Brain A E | 1972 | IEEE Trans1972，21，： | 1 |
| 17 | 显示文摘 | Marcus J A M | 1994 | J Organomet Chem1994，482，： | 1 |
| 18 | Software process validation:quantitatively measuring the correspondence of a process to a model显示文摘 | WOLF A L | 1999 | ACM Transactions on Software Engineering and Methodology1999，8，2： | 1 |
| 19 | 显示文摘 | Xiong X Eckelt J Wolf B A | 2006 | J Chromatogr A2006，1110，： | 1 |
| 20 | Preparation of coenzyme M analogues and their activity in the methylcoenzyme M reductase system of Methanobacterium thermoautotrophicum显示文摘 | Gunsalus R P Romesser J A Wolfe R S | 1978 | Biochemistry1978，17，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员